Begin main content

Search

We found 6643 result(s)

Evidence-to-Action: Accessing Mental Health Support Outside of a Therapist’s Office: iCBT for Major Depression and Anxiety Disorders

Event Date: November 27, 2019
Result type: Events

Internet-delivered cognitive behavioural therapy (iCBT) is a treatment option for people living with depression or anxiety disorders. This event will provide the opportunity to increase awareness around existing iCBT work in Canada and will facilitate a conversation between various stakeholders across the country. Join us online or in person as...

CADTH Medical Device and Drug Portfolio Information Sessions

Event Date: November 25, 2019
Result type: Events

These sessions will be presented in English and are available in person or via live broadcast. There is no charge to attend, but advance registration is required. Registration closes November 19, 2019. CADTH Medical Device Portfolio Information Session 10:00 a.m. to 12:00 p.m. EST Health technology assessment (HTA) plays a key role in decisi...

tildrakizumab (Ilumya )

Last Updated: November 22, 2019
Result type: Reports
Product Line: Common Drug Review
Generic Name: tildrakizumab
Indications: Psoriasis, moderate to severe plaque

  • Brand Name: Ilumya
  • Manufacturer: Sun Pharma Canada
  • Project Number: SR0624-000
  • Project Status: Active
  • Submission Type: New

Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma

Last Updated: November 22, 2019
Result type: Reports
Product Line: Therapeutic Review

Multiple myeloma (MM) is a hematological cancer that mainly affects individuals older than 65 years of age. Though MM remains incurable, several life-prolonging pharmacotherapies for the treatment of newly diagnosed, relapsed, or refractory MM were reviewed by CADTH and are available or being considered for public reimbursement in Canada. Howeve...

  • Project Number: TR0014-000

Call for Feedback: Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma

Published on: November 22, 2019
Result type: News

A new project on Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma is now available for feedback from all interested stakeholders. Optimal Pharmacotherapy for Transplant-Ineligible Multiple Myeloma Call for Feedback: 2019-11-22
Feedback Due By: 2019-12-06
Consultation Document: Proposed Project Scope
Product ...

Drug Reimbursement Recommendation - lanadelumab (Takhzyro) + certolizumab pegol (Cimzia)

Published on: November 22, 2019
Result type: News

Today, CADTH has issued final recommendations for: lanadelumab (Takhzyro) Indications: Hereditary angioedema, prevention
Recommendation: Reimburse with clinical criteria and/or conditions For more information certolizumab pegol (Cimzia) Indications: Psoriasis, moderate to severe plaque
Recommendation: Reimburse with clinical c...